Michael F Press

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens
    Michael F Press
    Breast Cancer Research Program of the Lee Breast Center, Department of Pathology, University of Southern California, Los Angeles, USA
    J Clin Oncol 20:3095-105. 2002
  2. doi request reprint Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
    Richard S Finn
    Geffen School of Medicine at UCLA, Norris Cancer Center, University of Southern California, Los Angeles, CA 90095, USA
    J Clin Oncol 27:5552-8. 2009
  3. ncbi request reprint HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033 0800, USA
    Clin Cancer Res 14:7861-70. 2008
  4. pmc A genome-wide association study of breast cancer in women of African ancestry
    Fang Chen
    Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Hum Genet 132:39-48. 2013
  5. pmc Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, CA, USA
    J Clin Oncol 29:859-67. 2011
  6. pmc A genome-wide scan for breast cancer risk haplotypes among African American women
    Chi Song
    Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    PLoS ONE 8:e57298. 2013
  7. pmc Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort
    Christopher A Haiman
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
    BMC Cancer 9:43. 2009
  8. pmc A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer
    Christopher A Haiman
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
    Nat Genet 43:1210-4. 2011
  9. pmc Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women
    Veronica Wendy Setiawan
    Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Cancer Genet Cytogenet 181:16-9. 2008
  10. doi request reprint A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach
    Carolyn D Britten
    Department of Medicine, University of California, Los Angeles, CA, USA
    Clin Breast Cancer 9:16-22. 2009

Detail Information

Publications45

  1. ncbi request reprint Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens
    Michael F Press
    Breast Cancer Research Program of the Lee Breast Center, Department of Pathology, University of Southern California, Los Angeles, USA
    J Clin Oncol 20:3095-105. 2002
    ..To compare and evaluate HER-2/neu clinical assay methods...
  2. doi request reprint Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
    Richard S Finn
    Geffen School of Medicine at UCLA, Norris Cancer Center, University of Southern California, Los Angeles, CA 90095, USA
    J Clin Oncol 27:5552-8. 2009
    ..We examined the prognostic and predictive role of HER2 ECD in a randomized trial of paclitaxel with placebo or lapatinib in women with HER2-negative or -unknown breast cancer...
  3. ncbi request reprint HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033 0800, USA
    Clin Cancer Res 14:7861-70. 2008
    ..Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy...
  4. pmc A genome-wide association study of breast cancer in women of African ancestry
    Fang Chen
    Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Hum Genet 132:39-48. 2013
    ..Identification of novel risk variants for breast cancer in women of African ancestry will demand testing of a substantially larger set of markers from stage 1 in a larger replication sample...
  5. pmc Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, CA, USA
    J Clin Oncol 29:859-67. 2011
    ..This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers...
  6. pmc A genome-wide scan for breast cancer risk haplotypes among African American women
    Chi Song
    Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    PLoS ONE 8:e57298. 2013
    ....
  7. pmc Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort
    Christopher A Haiman
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
    BMC Cancer 9:43. 2009
    ....
  8. pmc A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer
    Christopher A Haiman
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
    Nat Genet 43:1210-4. 2011
    ..25, P = 1.1 × 10(-9)), particularly in younger women (<50 years of age) (OR = 1.48, P = 1.9 × 10(-9)). Our results identify a genetic locus associated with estrogen receptor negative breast cancer subtypes in multiple populations...
  9. pmc Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women
    Veronica Wendy Setiawan
    Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Cancer Genet Cytogenet 181:16-9. 2008
    ..18, 95% CI = 0.76-1.82, P = 0.46). Our results do not support the hypothesis that the mtDNA G10398A polymorphism is, as has previously been reported, a marker of breast cancer risk in African Americans...
  10. doi request reprint A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach
    Carolyn D Britten
    Department of Medicine, University of California, Los Angeles, CA, USA
    Clin Breast Cancer 9:16-22. 2009
    ..This phase I/II trial was conducted to determine the toxicities, recommended dose, pharmacokinetics, and response rate of erlotinib plus trastuzumab in metastatic HER2+ breast cancer...
  11. ncbi request reprint Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials
    Michael F Press
    Women s Cancers Program, Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 89195, USA
    Clin Cancer Res 11:6598-607. 2005
    ....
  12. pmc Serum organochlorines and breast cancer: a case-control study among African-American women
    Nicole M Gatto
    Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, USC Norris Comprehensive Center, 1441 Eastlake Avenue, Room 4449, Los Angeles, CA 90033, USA
    Cancer Causes Control 18:29-39. 2007
    ..This study, the largest study of African-American women to date, does not support a role of DDE and total PCBs in breast cancer risk at the levels measured...
  13. pmc Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in
    Richard S Finn
    Geffen School of Medicine at University of California, Los Angeles, CA, USA
    J Clin Oncol 27:3908-15. 2009
    ..Published data support interactions between steroid hormone and peptide growth factor signaling. We hypothesized that molecular subgroups may exist within EGF30001 that would benefit from lapatinib...
  14. ncbi request reprint Lifetime recreational exercise activity and breast cancer risk among black women and white women
    Leslie Bernstein
    Department of Preventive Medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
    J Natl Cancer Inst 97:1671-9. 2005
    ....
  15. pmc Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans
    Fang Chen
    Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Hum Mol Genet 20:4491-503. 2011
    ..04, P = 6.1 × 10(-5)]. In this detailed analysis of the known breast cancer risk loci, we have validated and improved upon markers of risk that better characterize their association with breast cancer in women of African ancestry...
  16. ncbi request reprint A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans
    Christopher A Haiman
    Departments of Preventive Medicine and Pathology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
    Cancer Res 67:3565-8. 2007
    ..03) and stronger in those with advanced disease (411 cases and 877 controls; OR, 2.60; 95% CI, 1.56-4.34; P = 0.0002). These data suggest that African Americans harbor an allele at the POR locus that may increase breast cancer risk...
  17. ncbi request reprint Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 700 Westwood Plaza, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 17:315-23. 2004
    ..62 h) was similar. Thus, minibodies with different specificities display similar pharmacokinetics, while tumor uptake may vary depending on the antigen-antibody system...
  18. doi request reprint Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations
    Guido Sauter
    Department of Pathology and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, Ste 5409, Los Angeles, CA 90033
    J Clin Oncol 27:1323-33. 2009
    ..Until other methods achieve similar test accuracy, reproducibility, and predictive value, we suggest FISH as the primary HER-2 testing modality for women with breast cancer who are candidates for HER-2-targeted therapies...
  19. pmc Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    Antonio C Wolff
    Antonio C Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore Lisa M McShane, National Cancer Institute, Bethesda, MD M Elizabeth H Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT David G Hicks, University of Rochester Medical Center, Rochester, NY Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom Kimberly H Allison, Stanford University Medical Center, Stanford Patrick Fitzgibbons, St Jude Medical Center, Fullerton Michael F Press, University of Southern California, Los Angeles, CA Donald C Allred, Washington University School of Medicine, St Louis, MO John M S Bartlett, Ontario Institute for Cancer Research Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia Robert B Jenkins, Mayo Clinic, Rochester, MN Pamela B Mangu, American Society of Clinical Oncology, Alexandria, VA Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh,
    Arch Pathol Lab Med 138:241-56. 2014
    ....
  20. ncbi request reprint EGFR, HER2 and VEGF pathways: validated targets for cancer treatment
    Michael F Press
    Department of Pathology, Keck School of Medicine, Oncology, University of Southern California Norris Comprehensive Cancer Center, 14412 Eastlake Avenue, Los Angeles, CA 90033, USA
    Drugs 67:2045-75. 2007
    ..The results achieved with targeted therapies to date are promising, although they illustrate the need for additional preclinical and clinical study...
  21. pmc Receptor tyrosine kinase EphB4 is a survival factor in breast cancer
    S Ram Kumar
    Department of Pathology, Keck School of Medicine of the University of Southern California, 1441 Eastlake Avenue, NOR 6330, Los Angeles, CA 90033, USA
    Am J Pathol 169:279-93. 2006
    ..Our data indicate that biologically active EphB4 functions as a survival factor in breast cancer and is a novel target for therapy...
  22. doi request reprint Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
    Richard S Finn
    Authors Affiliations Geffen School of Medicine at UCLA Norris Cancer Center, University of Southern California, Los Angeles, California GlaxoSmithKline, Collegeville, Pennsylvania GlaxoSmithKline, Durham, North Carolina and Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 20:736-43. 2014
    ..The hypothesis that low hormone receptor status is associated with benefit in this HER2-negative cohort was tested...
  23. ncbi request reprint Characterization of HER2 Status by Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC)
    Oliver A Press
    Department of Pathology, USC Keck School of Medicine, Los Angeles, CA, USA
    Methods Mol Biol 1180:181-207. 2014
    ..This chapter provides a brief overview of pre-analytic and analytical processing of breast specimens as well as subsequent molecular evaluation for HER2 status. ..
  24. ncbi request reprint HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics
    Peter A Fasching
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Breast Cancer Res Treat 145:193-203. 2014
    ....
  25. pmc Genome-scale screen for DNA methylation-based detection markers for ovarian cancer
    Mihaela Campan
    Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
    PLoS ONE 6:e28141. 2011
    ..We developed a systematic multi-step biomarker discovery and verification strategy to identify candidate DNA methylation markers for the blood-based detection of ovarian cancer...
  26. ncbi request reprint Lifetime recreational exercise activity and risk of breast carcinoma in situ
    Alpa V Patel
    Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Cancer 98:2161-9. 2003
    ..Because of its potential effects on circulating sex hormones, physical activity has been proposed as a modifiable risk factor for invasive breast carcinoma. However, the relation to BCIS risk is poorly understood...
  27. ncbi request reprint Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
    David B Agus
    Cedars Sinai Prostate Cancer Center and Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 23:2534-43. 2005
    ..A clinical study was conducted to investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HER dimerization inhibition as a treatment strategy...
  28. pmc Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial
    Linda Hovanessian-Larsen
    Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Contraception 86:238-43. 2012
    ....
  29. ncbi request reprint Antibody-mediated targeting of replication-competent retroviral vectors
    Chien Kuo Tai
    Institute for Genetic Medicine, Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Hum Gene Ther 14:789-802. 2003
    ..Application of antibody-mediated targeting to the initial localization of replication-competent virus vectors to tumor sites will thus require optimized target selection and vector design...
  30. ncbi request reprint P7 antigen expression in human breast cancer
    Xiaowei Yang
    Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Clin Cancer Res 9:201-6. 2003
    ..Evaluate p7 expression in human breast cancer and determine whether chemotherapy and radiation therapy effect a change in p7 expression...
  31. ncbi request reprint Identification of TP53 mutations in human cancers using oligonucleotide microarrays
    Wen Hsiang Wen
    Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    Methods Mol Med 97:323-35. 2004
  32. ncbi request reprint The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results
    Polly A Marchbanks
    Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Ann Epidemiol 12:213-21. 2002
    ..This paper presents methods and operational results of a population-based case-control study examining the effects of oral contraceptive use on breast cancer risk among white and black women aged 35-64 years in five U.S. locations...
  33. ncbi request reprint Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women's Contraceptive and Reproductive Experiences Study
    Michael S Simon
    Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University, Detroit, MI 48201, USA
    J Clin Oncol 24:2498-504. 2006
    ..The purpose of this report is to update breast cancer risk estimates associated with a family history of breast cancer for white and AA women...
  34. ncbi request reprint Racial differences in the familial aggregation of breast cancer and other female cancers
    Michael S Simon
    Division of Haematology and Oncology, Barbara Ann Karmanos Cancer Institute, 4100 John R, 4221 Hudson, Weber Cancer Research Building, Detroit, M1 48201, USA
    Breast Cancer Res Treat 89:227-35. 2005
    ..17 (1.22-3.85). In conclusion, these racially distinct aggregation patterns may reflect different modes of inheritance and/or environmental factors that impact cancer risk...
  35. ncbi request reprint Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab
    Robert D Mass
    Genentech, Inc, South San Francisco, CA 94080, USA
    Clin Breast Cancer 6:240-6. 2005
    ..Breast cancer tissue specimens were evaluated using a direct labeled, dual-probe FISH assay...
  36. ncbi request reprint Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab
    Noel Dybdal
    Genentech Inc, South San Francisco, CA 94080, USA
    Breast Cancer Res Treat 93:3-11. 2005
    ..The IHC protocol used was a research assay, known as the Clinical Trial Assay (CTA), developed to select women with metastatic breast cancer (MBC) for three pivotal clinical trials of trastuzumab therapy...
  37. ncbi request reprint Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer
    Mark D Pegram
    Oncology Research Network, David Geffen School of Medicine, and Division of Hematology Oncology, University of California, Los Angeles 90095 7077, USA
    J Natl Cancer Inst 96:759-69. 2004
    ....
  38. ncbi request reprint HER2 testing in breast cancer: NCCN Task Force report and recommendations
    Robert W Carlson
    Stanford Hospital and Clinics
    J Natl Compr Canc Netw 4:S1-22; quiz S23-4. 2006
    ..8 to 2.2 or average number of HER2 gene copies/cell in the range of greater than 4 to less than 6 are considered to be borderline, and strategies to assign the HER2 status of such samples are proposed...
  39. ncbi request reprint Oral contraceptive use and risk of breast carcinoma in situ (United States)
    Jasmeet K Gill
    Etiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA
    Cancer Causes Control 17:1155-62. 2006
    ..Our study assesses the impact of oral contraceptive use on breast carcinoma in-situ (BCIS) risk...
  40. ncbi request reprint How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified?
    Michael F Press
    Am J Clin Pathol 126:673-4. 2006
  41. ncbi request reprint American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...
  42. pmc Timing of menarche and first full-term birth in relation to breast cancer risk
    Christopher I Li
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Am J Epidemiol 167:230-9. 2008
    ..The authors conclude that the interval between age at menarche and age at first birth is associated with the risk of hormonally sensitive types of breast cancer, particularly among White women...
  43. ncbi request reprint Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California at Los Angeles, 90095, USA
    Cancer Res 65:5907-16. 2005
    ..1 +/- 1.5% ID/g). Thus, by manipulating the size and format of anti-p185(HER2) antibody fragments, the kidney activity was reduced and high or low expression of p185HER2 in xenografts could be distinguished by microPET imaging...
  44. ncbi request reprint Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'
    Marc E Lippman
    Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109 0368, USA
    Breast Cancer Res Treat 90:1-3. 2005
  45. ncbi request reprint Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer
    Christopher I Li
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4 C308, P O Box 19024, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 15:946-54. 2006
    ....